Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Market Cap	1.12T
Revenue (ttm)	8.41B
Net Income (ttm)	-22.86B
Shares Out	30.11M
EPS (ttm)	-764.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,109
Average Volume	91,080
Open	37,350
Previous Close	37,050
Day's Range	36,800 - 38,800
52-Week Range	25,450 - 43,300
Beta	0.23
RSI	49.02
Earnings Date	Aug 12, 2025

About Mezzion Pharma

Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 19
• Stock Exchange: KOSDAQ
• Ticker Symbol: 140410

Financial Performance

In 2024, Mezzion Pharma's revenue was 8.61 billion, a decrease of -72.85% compared to the previous year's 31.72 billion. Losses were -19.48 billion, 53.0% more than in 2023.